Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD) $10.53 +0.23 (+2.23%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$10.16▼$10.6250-Day Range$8.79▼$10.5352-Week Range$8.07▼$12.66Volume2.29 million shsAverage Volume2.29 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$20.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Ironwood Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside96.3% Upside$20.67 Price TargetShort InterestBearish11.25% of Float Sold ShortDividend StrengthN/ASustainability-2.94Upright™ Environmental ScoreNews Sentiment-0.10Based on 4 Articles This WeekInsider TradingAcquiring Shares$300,119 Bought Last QuarterProj. Earnings Growth-40.19%From $1.07 to $0.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector605th out of 952 stocksPharmaceutical Preparations Industry285th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.67, Ironwood Pharmaceuticals has a forecasted upside of 96.3% from its current price of $10.53.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.25% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently decreased by 1.38%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIronwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ironwood Pharmaceuticals is -2.94. Previous Next 1.6 News and Social Media Coverage News SentimentIronwood Pharmaceuticals has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ironwood Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for IRWD on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $300,119.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.10% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to decrease by -40.19% in the coming year, from $1.07 to $0.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIronwood Pharmaceuticals has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More IRWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRWD Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comZacks Research Comments on Ironwood Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:IRWD)November 27, 2023 | msn.comIronwood Pharmaceuticals Inc - (IRWD) Price Target Increased by 5.45% to 17.75December 5, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. November 21, 2023 | finance.yahoo.comIronwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 10, 2023 | insidermonkey.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Ironwood Pharmaceuticals Inc Earnings CallNovember 9, 2023 | msn.comJefferies starts Ironwood at buy, cites potential of drug apraglutideNovember 9, 2023 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call PresentationDecember 5, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. November 9, 2023 | finance.yahoo.comIronwood Pharmaceuticals Reports Third Quarter 2023 ResultsOctober 26, 2023 | finance.yahoo.comIronwood Pharmaceuticals to Host Third Quarter 2023 Investor Update CallOctober 23, 2023 | finance.yahoo.comIronwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific MeetingOctober 17, 2023 | gurufocus.comDecoding Ownership and Performance: Ironwood Pharmaceuticals Inc(IRWD)October 16, 2023 | markets.businessinsider.comIronwood Pharma Reveals Positive Final Data From STARS Nutrition Phase II Study Of ApraglutideOctober 16, 2023 | finance.yahoo.comIronwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology WeekOctober 5, 2023 | finance.yahoo.comIronwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-OldOctober 4, 2023 | msn.comIronwood Pharmaceuticals Inc - (IRWD) Price Target Increased by 12.50% to 16.83October 3, 2023 | finance.yahoo.comIronwood Pharmaceuticals (IRWD): A Hidden Gem or a Potential Risk? An In-Depth Look at Its ValuationOctober 1, 2023 | finance.yahoo.comHere's How to Lock in a Trade on a Promising Biopharma NameSeptember 29, 2023 | msn.comJMP Securities Initiates Coverage of Ironwood Pharmaceuticals Inc - (IRWD) with Market Outperform RecommendationSeptember 28, 2023 | msn.comJMP starts Ironwood at market outperform, cites potential of GLP-2 drugSeptember 28, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mirati Therapeutics (MRTX) and Ironwood Pharma (IRWD)September 26, 2023 | finance.yahoo.comUnveiling Ironwood Pharmaceuticals (IRWD)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 19, 2023 | finance.yahoo.comIronwood Pharmaceuticals (IRWD): A Comprehensive Analysis of Its Market ValueSeptember 19, 2023 | finance.yahoo.comIronwood Pharmaceuticals Inc (IRWD): A Deep Dive into Its Performance PotentialSeptember 12, 2023 | finance.yahoo.comImplied Volatility Surging for Ironwood (IRWD) Stock OptionsAugust 26, 2023 | msn.comIronwood: Pipeline Progresses As FDA Approves LINZESSSee More Headlines Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees219Year FoundedN/APrice Target and Rating Average Stock Price Target$20.67 High Stock Price Target$22.00 Low Stock Price Target$19.00 Potential Upside/Downside+96.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($6.23) Trailing P/E RatioN/A Forward P/E Ratio9.84 P/E GrowthN/ANet Income$175.07 million Net Margins-220.24% Pretax Margin-209.57% Return on Equity112.29% Return on Assets22.80% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual Sales$410.60 million Price / Sales4.00 Cash Flow$1.17 per share Price / Cash Flow9.00 Book Value$4.24 per share Price / Book2.48Miscellaneous Outstanding Shares156,130,000Free Float135,676,000Market Cap$1.64 billion OptionableOptionable Beta0.84 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Julie H. McHugh (Age 59)Executive Chairman of the Board Comp: $95kMr. Thomas A. McCourt (Age 66)CEO & Director Comp: $1.42MMr. Sravan Kumar Emany (Age 45)Senior VP, Principal Financial Officer & CFO Comp: $712.36kMr. John Minardo (Age 47)Senior VP, Chief Legal Officer & Secretary Comp: $675.88kDr. Michael Shetzline M.D. (Age 64)Ph.D., Chief Medical Officer, Senior VP and Head of Research & Drug Development Comp: $837.74kMr. Ronald Silver (Age 41)Corporate Controller & Principal Accounting Officer Mr. Marcel MoulaisonVice President of Technical OperationsGreg MartiniVice President of Strategic Finance & Investor RelationsMs. Beth CalitriHead of Corporate Communications & Media RelationsMr. Mike NanfitoVice President of Sales & Sales ExcellenceMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXOPKO HealthNASDAQ:OPKGeronNASDAQ:GERNLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 89,441 shares on 11/30/2023Ownership: 0.821%Public Sector Pension Investment BoardSold 70,188 shares on 11/22/2023Ownership: 0.109%Walleye Capital LLCBought 166,968 shares on 11/21/2023Ownership: 0.107%Comerica BankBought 55,493 shares on 11/21/2023Ownership: 0.036%Jacobs Levy Equity Management Inc.Bought 2,378,295 shares on 11/17/2023Ownership: 1.524%View All Insider TransactionsView All Institutional Transactions IRWD Stock Analysis - Frequently Asked Questions Should I buy or sell Ironwood Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares. View IRWD analyst ratings or view top-rated stocks. What is Ironwood Pharmaceuticals' stock price target for 2024? 2 brokers have issued 1 year target prices for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $19.00 to $22.00. On average, they predict the company's stock price to reach $20.67 in the next year. This suggests a possible upside of 96.3% from the stock's current price. View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts. How have IRWD shares performed in 2023? Ironwood Pharmaceuticals' stock was trading at $12.39 at the start of the year. Since then, IRWD stock has decreased by 15.0% and is now trading at $10.53. View the best growth stocks for 2023 here. When is Ironwood Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our IRWD earnings forecast. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to the consensus estimate of $112.90 million. Ironwood Pharmaceuticals had a positive trailing twelve-month return on equity of 112.29% and a negative net margin of 220.24%. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 EPS. What ETFs hold Ironwood Pharmaceuticals' stock? ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Biotech ETF (XBI) and Pacer US Small Cap Cash Cows 100 ETF (CALF). What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings? Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $441.42 million. What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO? 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX). Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (4.59%), Victory Capital Management Inc. (2.82%), Armistice Capital LLC (2.21%), Adage Capital Partners GP L.L.C. (1.58%), Jacobs Levy Equity Management Inc. (1.52%) and Jupiter Asset Management Ltd. (1.42%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IRWD) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.